clinical trial · NCT06886620
Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication
Genovate Biotechnology Co., Ltd.,·phase3·terminated·n = 14
Intermittent ClaudicationCilostazol 200 mgCilostazol 100 mg
brief summary
The study is designed to compare the efficacy and safety of once daily PMR treatment with twice daily Pletaal® treatment in patients with intermittent claudication caused by peripheral arterial disease and are currently treated with cilostazol of any strength and any dosing frequency.
started
Mar 14, 2016
primary completion
Feb 8, 2017
completion
Feb 8, 2017
last updated
Mar 20, 2025
official title
A Phase III Prospective, Randomized, Double Blind, Active Controlled, Multicenter, Parallel Group Study to Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol